<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01832103</url>
  </required_header>
  <id_info>
    <org_study_id>7145-018</org_study_id>
    <secondary_id>2013-000838-35</secondary_id>
    <nct_id>NCT01832103</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)</brief_title>
  <official_title>A Phase I Study to Evaluate the Pharmacokinetics of MK-7145 Following Single Dose Administration in Patients With Moderate Renal Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to obtain a preliminary pharmacokinetic profile of&#xD;
      MK-7145 2 mg immediate release (IR) following single-dose administration in male participants&#xD;
      with moderate renal insufficiency. In addition, the study will evaluate the pharmacodynamic&#xD;
      effect of a single dose of MK-7145 2 mg IR on 24-hour net natriuresis in male participants&#xD;
      with moderate renal insufficiency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma-Time Curve From 0 to Infinity (AUC0-∞) of MK-7145 2 mg IR Following Single Dose Administration</measure>
    <time_frame>Up to 48 Hours Post Dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of MK-7145 2 mg IR Following Single Dose Administration</measure>
    <time_frame>Up to 48 Hours Post Dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of MK-7145 2 mg IR Following Single Dose Administration</measure>
    <time_frame>Up to 48 Hours Post Dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Half-Life (t 1/2) of MK-7145 2 mg IR Following Single Dose Administration</measure>
    <time_frame>Up to 48 Hours Post Dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Clearance (CL/F) of MK-7145 2 mg IR Following Single Dose Administration</measure>
    <time_frame>Up to 24 Hours Post Dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Volume of Distribution (V/F) of MK-7145 2 mg IR Following Single Dose Administration</measure>
    <time_frame>Up to 48 Hours Post Dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-Hr Urine Natriuresis (UNa0-24)</measure>
    <time_frame>24 Hours Prior to Dosing (Baseline) and Up to 24 Hours Post Dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>MK-7145</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-7145 2 mg IR administered as a single oral dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-7145</intervention_name>
    <arm_group_label>MK-7145</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) 18 to 35 kg/m^2&#xD;
&#xD;
          -  Nonsmoker and/or have not used nicotine or nicotine-containing products&#xD;
&#xD;
        for at least 3 months prior to enrollment&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) 30 to 60 mL/min/1.73 m^2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of stroke, chronic seizures, or major neurological disorder&#xD;
&#xD;
          -  Ongoing, clinically significant endocrine, gastrointestinal, cardiovascular,&#xD;
&#xD;
        hematological, hepatic, immunological, respiratory, or genitourinary abnormalities or&#xD;
        diseases&#xD;
&#xD;
          -  Systolic blood pressure (SBP) ≤95 mmHg or &gt;160 mmHg, or diastolic blood&#xD;
&#xD;
        pressure (DBP) ≤45 mmHg or &gt;95 mmHg&#xD;
&#xD;
          -  History of neoplastic disease except for adequately treated non-melanomatous skin&#xD;
             carcinoma&#xD;
&#xD;
          -  Unable to refrain from, or anticipates the use of, strong/moderate cytochrome P450 3A4&#xD;
             (CYP3A4) inhibitors&#xD;
&#xD;
          -  Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic&#xD;
             beverages, wine, or distilled spirits per day&#xD;
&#xD;
          -  Consumes excessive amounts of caffeine, defined as greater than 6 servings of coffee,&#xD;
             tea, cola, or other caffeinated beverages per day&#xD;
&#xD;
          -  Had major surgery or donated blood within 8 weeks prior to enrollment&#xD;
&#xD;
          -  Has participated in another investigational study within 4 weeks prior&#xD;
&#xD;
          -  History of significant multiple and/or severe allergies (including latex allergy), or&#xD;
             has had an anaphylactic reaction or significant intolerance to prescription or&#xD;
             nonprescription drugs or food&#xD;
&#xD;
          -  Currently a regular user of illicit drugs, or has a history of drug (including&#xD;
             alcohol) abuse within approximately 6 months&#xD;
&#xD;
          -  Has active or has a history of nephrolithiasis&#xD;
&#xD;
          -  Has had a kidney removed or has a functioning renal transplant&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>April 11, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

